Publications

Featured Publications

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method

Cuker A, Despotovic JM, Grace RF, Kruse C, Lambert MP, Liebman HA, Lyons RM, McCrae KR, Pullarkat V, Wasser JS, Beenhouwer D, Gibbs SN, Yermilov I, Broder MS

Research and Practice in Thrombosis and Haemostasis

2020

Download

Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States

Broder MS, Ma Q, Yan T, Zhang J, Chang E, Kuzan D, Eldjerou L

American Health & Drug Benefits

2020

Download

Development of a Severity Classification System for Sickle Cell Disease

Shah N, Beenhouwer D, Broder MS, Bronte-Hall L, De Castro LM, Gibbs SN, Gordeuk VR, Kanter J, Klings ES, Lipato T, Manwani D, Scullin B, Yermilov I, Smith WR

ClinicoEconomics and Outcomes Research

2020

Download

The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis

Vera-Llonch M, Reddy SR, Chang E, Tarbox MH, Pollock M

Orphanet Journal of Rare Diseases

2021

Download

2021

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method

Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States

Development of a Severity Classification System for Sickle Cell Disease

The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis

Burden of illness among US Medicare beneficiaries with late-onset Huntington’s disease

Burden of illness among US Medicare beneficiaries with late-onset Huntington’s disease

Cardiovascular Disease Burden Before Hereditary Transthyretin Amyloidosis Diagnosis Among Medicare Beneficiaries

Cardiovascular Symptom Burden Prior to Diagnosis of Transthyretin Amyloidosis Among Medicare Beneficiaries

Healthcare utilization and costs among US Medicaid beneficiaries with Huntington’s disease

National Burden of Achondroplasia in Adults and Children: An Analysis of the National Inpatient Sample

Symptom Burden and Healthcare Utilization Before Diagnosis of Transthyretin-Mediated Amyloidosis Among Medicare Beneficiaries

The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis

Use of Commercial Claims Data to Estimate Hereditary Transthyretin-Mediated Amyloidosis Prevalence and Incidence in the US

Use of Commercial Claims Data to Estimate Transthyretin-Amyloid Cardiomyopathy Prevalence and Incidence in the US

Burden of disease in pediatric narcolepsy: a claims-based analysis of health care utilization, costs, and comorbidities

Burden of Nasal Polyps in the United States

Cardiovascular Burden Prior to Diagnosis of Hereditary Transthyretin Amyloidosis

Cardiovascular Burden Prior to Diagnosis of Hereditary Transthyretin Amyloidosis

Despite Increases in Rate of Hospitalization, In-Hospital Mortality and Admission Costs Associated With Melanoma of the Skin Have Remained Stable From 2012-2016

Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States

Epidemiology of Huntington’s disease (HD) in the US Medicare population

Epidemiology of Huntington’s disease in the US Medicaid population

Epidemiology of Huntington’s disease in the US Medicaid population

Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy

Healthcare resource use and cost in antifibrotic-treated vs untreated patients with idiopathic pulmonary fibrosis (IPF) in the US Medicare population

Healthcare Resource Utilization and Costs in Medicare Beneficiaries With Parkinson’s Disease

Healthcare Use and Costs Among Medicare Enrollees on Pirfenidone Versus Nintedanib for Idiopathic Pulmonary Fibrosis

Healthcare utilization and cost burden at the end of life among Medicare beneficiaries with Huntington’s disease